<DOC>
	<DOCNO>NCT02360358</DOCNO>
	<brief_summary>A prospective , multicenter , randomise control phase II study patient therapy resistant ( arterio- ) venous leg/foot ulcer treat Tiscover® ( test group ) AS210 ( control group ) determine safety relative efficacy product .</brief_summary>
	<brief_title>Autologous Skin Substitute Chronic Leg/Foot Ulcers .</brief_title>
	<detailed_description>Multicenter , randomise clinical trial patient patient chronic ( arterio- ) venous leg/foot ulcer treat autologous cultured human living skin substitute ( Tiscover® : test group ) Acellular donor dermis ( AS210 : control group ) . During pre-inclusion evaluation period 4 week ( non heal ) chronicity ulcer ensure ( ulcer size change &lt; 30 % ) . To determine ulcer type ABI , Doppler CEAP perform . The test group receive 2 application Tiscover® . Week 0 : wound activate pre-treatment , application least one quarter wind surface . Week 1 : removal patch , application patch total wound surface . The control group ( 16 patient ) follow application protocol .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Inclusion criterion : Have ( arterio ) venous leg ulcer ( VLU ) knee ankle ( malleolus ) , foot ( plantar side foot ) surface area ≥ 1.0 cm2 ≤ 40.0 cm2 Venous insufficiency confirm duplex Doppler ultrasound examination valvular venous incompetence . Arterial supply adequacy confirm ( ABPI ≥ 0.6 ≤ 1.3 ) Target ulcer involve full thickness skin loss , WITHOUT exposure tendon , muscle , bone . Ulcer depth &lt; 1 cm Target ulcer duration ≥ 12 week ≤ 15 year Acceptable state health nutrition Mobile , least able walk medical walker , able return require treatment study evaluation History anaphylaxis , serum sickness , erythema multiforme reaction bovine serum protein , gentamycin . Therapy another investigational agent within thirty ( 30 ) day Screening , study . A target ulcer nonvenous etiology ( e.g. , sickle cell anemia , necrobiosis lipoidica diabeticorum , pyoderma gangrenosum , vasculopathic vasculitic ) . Documented history osteomyelitis target wound location within 6 month precede Screening Visit . Refusal inability tolerate compression therapy . Therapy target ulcer autologous skin graft , Apligraf™ , Dermagraft™ within 30 day precede Screening Visit . History cancer precede 5 year ( carcinoma situ cervix adequately treat nonmelanoma skin cancer ) . &gt; 30 % change wind size 4 week confirm historical data Presence deep vein thrombosis contra indication compression therapy Severe comorbidity reduce life expectance &lt; 1 year Use oral corticosteroid and/or cytostatics &gt; 20 mg/per day ; Severe infection ulcer , active cellulitis , osteomyelitis Severe malnutrition Uncontrolled diabetes mellitus , HbA1c &gt; 12 % ( 108 mmol/mol ) Anaemia Hb &lt; 6 mmol/l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>